Search clinical trials for: Tocilizumab Infusion RoAcemtra (EU)

Total 181 results

University Hospital Tuebingen

Completed

Tocilizumab for the Treatment of Familial Mediterranean Fever

Familial Mediterranean Fever

Germany
Rigshospitalet, Denmark

Completed

IL-6 Regulation of Substrate Metabolism and Influence of Obesity

Healthy | Obesity

Denmark
Hoffmann-La Roche

Completed

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Healthy Volunteer

France
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Serbia, Georgia, Russian Federation, Slovakia, Czechia, Bulgaria, Moldova, Republic of, Poland
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

Rheumatoid Arthritis

Kazakhstan
Hoffmann-La Roche

Completed

Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Austria
Hoffmann-La Roche

Completed

An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment

Rheumatoid Arthritis

Tunisia
Celltrion

Recruiting

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Healthy Subjects

Korea, Republic of
Hoffmann-La Roche

Completed

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA) (SIMPACT)

Rheumatoid Arthritis

Hungary
Hoffmann-La Roche
nv Roche sa

Completed

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Rheumatoid Arthritis

Belgium, Luxembourg
Papworth Hospital NHS Foundation Trust
Roche Pharma AG; National Institute for Health Research, United Kingdom

Completed

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension (TRANSFORM-UK)

Pulmonary Arterial Hypertension

United Kingdom
Hoffmann-La Roche

Completed

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Rheumatoid Arthritis

Slovakia
Hoffmann-La Roche

Completed

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
Karoline Krause
Roche Pharma AG

Completed

Tocilizumab in Patients With Schnitzler's Syndrome (TOCISCH)

Schnitzler's Syndrome

Germany
Hoffmann-La Roche

Completed

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Brazil
Hoffmann-La Roche

Terminated

An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Russian Federation, Poland
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs

Rheumatoid Arthritis

Finland
Hoffmann-La Roche

Completed

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) (JIGSAW 117)

Juvenile Idiopathic Arthritis

Spain, Mexico, Germany, United States, Russian Federation, Australia, Italy, Argentina, Brazil, Canada, France, United Kingdom
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

Juvenile Idiopathic Arthritis

France
Hoffmann-La Roche

Completed

An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study

Juvenile Idiopathic Arthritis

Brazil
Hoffmann-La Roche

Completed

An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

Rheumatoid Arthritis

Belgium, Czech Republic, France, Italy, Spain, Sweden, United Kingdom, Canada, Greece, Ireland, Portugal, Turkey, Netherlands, Denmark, Finland, Germany, Luxembourg, Austria, Switzerland, Poland, Australia, Hungary, Saudi Arabia, Romania and more
Hoffmann-La Roche

Completed

A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

United Arab Emirates, Kuwait, Bahrain, Iran, Islamic Republic of, Qatar
Centre Hospitalier Régional d'Orléans
Rennes University Hospital

Recruiting

Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis (REPAIR)

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Argentina, Germany, Italy, Russian Federation, Spain, Mexico, Australia, France
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Rheumatoid Arthritis

Saudi Arabia
Hoffmann-La Roche

Completed

A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Philippines
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.

Rheumatoid Arthritis

Israel
Hoffmann-La Roche

Completed

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

Juvenile Idiopathic Arthritis

Germany
Hoffmann-La Roche

Completed

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Spain
Hoffmann-La Roche

Completed

Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Rheumatoid Arthritis

Germany
Genentech, Inc.

Completed

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Rheumatoid Arthritis

United Kingdom
Hoffmann-La Roche

Completed

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Spain
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

Rheumatoid Arthritis

Morocco
Hoffmann-La Roche

Completed

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Germany, Italy, Russian Federation, Spain, Australia, France, Mexico, Argentina
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Giant Cell Arteritis

Switzerland
Hoffmann-La Roche

Terminated

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Poland
Hoffmann-La Roche

Completed

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

Rheumatoid Arthritis

Belgium, Luxembourg
Hoffmann-La Roche
Clalit Health Services

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Rheumatoid Arthritis

Israel
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926

Rheumatoid Arthritis

Macedonia, The Former Yugoslav Republic of
Hoffmann-La Roche

Completed

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

Castleman's Disease

United States
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Turkey
Hoffmann-La Roche

Completed

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Rheumatoid Arthritis

Denmark, Iceland
Hoffmann-La Roche

Completed

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Rheumatoid Arthritis

Czech Republic, France, Italy, Spain, United Kingdom, Canada, Portugal, Netherlands, Poland, Australia, Saudi Arabia, Romania, Hungary, Greece
Assistance Publique - Hôpitaux de Paris
Roche Pharma AG; Roche Chugai

Recruiting

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (TOGIAC)

Giant Cell Arteritis | Neurovascular Disorder

France
Hoffmann-La Roche

Completed

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Juvenile Idiopathic Arthritis

Belgium, Canada, United States, Argentina, Poland, Spain, Germany, Hungary
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

Rheumatoid Arthritis

China
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

Healthy

New Zealand

3

Subscribe